Of the roughly $23.3 billion in sales growth seen by 45 top pharmaceutical products, $14.3 billion of that has been tied to price increases, not demand.
Three months after President Trump announced his blueprint to bring down drug prices, administration officials have begun putting some teeth behind the rhetoric.
Digital ads for prescriptions are approaching parity with TV ads, with an even larger percentage of patients who saw ads online asking their doctors about specific medications.
The pharmaceutical industry fears major legislation that would curb prices and shrink profits, and has launched campaigns against it—but how honest are their claims?
The most recent new treatment for Alzheimer’s disease was approved by European regulators in May 2002, with the US FDA following suit the next year.
Recent lawsuits are asking courts whether the current crisis is comparable to the one over tobacco in the ’90s.
The possibility of curing sepsis with a common vitamin has put one of history’s greatest killers back in the spotlight.
Scientists invented chemical weapons; some are now working to destroy them.
A new study found that Big Pharma makes more from high U.S. drug prices than it spends on research around the world.
There are few new drugs on the horizon for diabetes, which affects about 29 million Americans.